

Special article

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management



Management of critical bleeding

Luciana Correa Oliveira^a, Juan Carlos Montano-Pedroso^{b,c},
Fernanda Vieira Perini^{d,e}, Roseny dos Reis Rodrigues^{f,g}, Enis Donizetti^h,
Silvia Renata Cornélio Parolin Rizzoⁱ, Guilherme Rabello^{id,j,*},
Dante Mario Langhi Junior^k

^a Hemocentro de Ribeirão Preto, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP), Ribeirão Preto, SP, Brazil

^b Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil

^c Instituto de Assistência Médica do Servidor Público Estadual (Iamspe), São Paulo, SP, Brazil

^d Grupo GSH – Gestor de Serviços de Hemoterapia, São Paulo, SP, Brazil

^e Associação Beneficente Síria HCOR, São Paulo, SP, Brazil

^f Hospital Israelita Albert Einstein São Paulo, São Paulo, SP, Brazil

^g Faculdade de Medicina da Universidade de São Paulo (FM USP), São Paulo, SP, Brazil

^h Hospital Sírio Libanês, São Paulo, SP, Brazil

ⁱ Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), São Paulo, SP, Brazil

^j Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Incor – HCFMUSP), São Paulo, SP, Brazil

^k Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM UNIFESP), São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Received 9 February 2024

Accepted 18 February 2024

Available online 13 March 2024

Keywords:

Critical bleeding

Severe bleeding

Massive transfusion protocol

Patient-centered approach

Patient blood management

ABSTRACT

The management of major bleeding is a critical aspect of modern healthcare and it is imperative to emphasize the importance of applying Patient Blood Management (PBM) principles. Although transfusion support remains a vital component of bleeding control, treating severe bleeding goes beyond simply replacing lost blood. A more comprehensive, multidisciplinary approach is essential to optimize patient outcomes and minimize the risks associated with excessive transfusions.

© 2024 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Incor – HCFMUSP), São Paulo, SP, Brazil.

E-mail address: grabello.inovaincor@fz.org.br (G. Rabello).

<https://doi.org/10.1016/j.htct.2024.02.009>

2531-1379/© 2024 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Severe hemorrhage is the leading cause of death in a variety of clinical scenarios, such as trauma, in the military or with civilians, and high-risk surgeries.¹⁻³ The management of severe hemorrhages involves early recognition of blood loss, control of acute bleeding and replacement of intravascular volume and deficient blood components, generally involving blood transfusion in a regime known as massive transfusion. Delay in starting appropriate transfusion is associated with increased mortality and morbidity.^{4,5}

In trauma patients with acute blood loss, immediate resuscitation, involving the use of blood components, has proven to be important in reducing mortality, bearing in mind that uncontrolled hemorrhage is the cause of up to 50 % of deaths within 24 h after traumatic injury.⁶

To enable the rapid availability of blood components, trauma centers, in recent decades, have adopted Massive Hemorrhage Protocols (MHP) or standardized criteria for releasing transfusions to arriving patients.⁷ In fact, the establishment of an institutional MHP has been recommended by several societies.⁸⁻¹⁰

The objective of this review is to assist healthcare professionals in establishing a MHP for the in-hospital management of adults with critical bleeding resulting from severe hemorrhage.

Definitions

To address the topic, some definitions are important:

- **Critical bleeding**

Critical bleeding is a term used to describe a variety of clinical scenarios in which bleeding may result in significant patient morbidity or mortality.

Generally speaking, critical bleeding falls into one of the following categories (which may overlap):

1. Severe bleeding that threatens life and may result in the need for a massive transfusion (transfusion greater than or equal to 5 units of packed red blood cells within 4 h).^{8,11,12}
2. Smaller-volume hemorrhage involving a critical area or organ (e.g., intracranial, intraspinal or intraocular) which may result in patient morbidity or mortality.

For this document, the term critical bleeding refers only to the first category.

- **Massive transfusion**

Massive transfusion (MT) is defined based on the volume of blood loss or the volume transfused. There are several definitions proposed by different groups.

For this document, MT is defined as a transfusion greater than or equal to 5 units of packed red blood cells within 4 h.⁸

- **Massive Hemorrhage Protocol (MHP)**

Given the current context of PBM, preference has been given to using the term critical bleeding management or Massive Bleeding Protocol (MHP), instead of the MT Protocol as it is a more comprehensive, multidisciplinary approach, which involves actions in addition to transfusion support for hemorrhagic control, correction of coagulopathies and normalization of physiological parameters.

Massive hemorrhage protocol (MHP)

A MHP model is suggested in [Figure 1](#).




Figure 1 – Massive hemorrhage protocol model.

MPH: Massive hemorrhage protocol.

Optimize	Repeat evaluation	Critical targets	
Oxygenation	(at least each	Temperature	Platelets >
Heart function	4 units of	≥ 35 °C	50×10 ⁹ /L
tissue perfusion	red blood	pH ≥ 7.2	TP/TTPA ≤
Metabolic state	cell concen- trate)	Excess base ≥	1.5 x nor- mal
	Complete	Lactate ≤	INR ≤ 1.5
	blood count	4 mmol/L	Fibrinogen
	Coagulation	Ca ²⁺ ≥	≥ 2.0 g/L
	tests	1.0 mmol/L	
	Ionic calcium		
	Gasometry		

Adapted from the National Blood Authority, 2023⁸
 Some aspects of the MHP deserve special attention and are highlighted in Figure 2.

When/How to implement the MHP and when to discontinue

MTs are responsible for more than 70 % of the blood transfused in trauma centers.^{13,14} Even in trauma centers with established MHP protocols, the incidence of over-transfusion can reach 27 %.¹⁵ Terminating these transfusions at the appropriate time minimizes the waste of this expensive and limited resource.

Considering the principles of PBM, it is essential to establish guidelines for both the implementation and discontinuation of the MHP aiming at adequate use of blood components and minimizing losses/waste.

The decision to implement a MHP is not an easy one. The decision to implement is often made too early and can result in a waste of blood components.

In this sense, multiple prediction scores and algorithms have been proposed to identify patients in need of MT. Many are complex, requiring difficult calculations and time-consuming laboratory tests, while some are simple and easy to remember, using physiological parameters, lesion characteristics and/or simple procedures such as point of care. The variables most commonly used in these models include: systolic blood pressure (SBP), heart rate (HR) and hemoglobin level (Hb). The results of base deficit, serum lactate, international normalized ratio (INR) and focused assessment for the sonography of trauma (FAST) are also used as covariates in some models.¹⁶

There is no consensus on a specific perfect score. They all lack prospective validation and each scoring system has its advantages, disadvantages and most useful scenarios, which affect their applicability on a broad scale.^{9,16}

Some factors need to be considered when deciding to implement a MHP, such as the cause of hemorrhage and the rate of blood loss, the mechanism of trauma (if any), the current physiological state of the individual and the likely need for continued support using blood components. Thus, it is




Figure 2 – Classification and categorization of the massive transfusion score.

SBP: Systolic blood pressure; RR: Respiratory rate HR: heart rate; Hb: hemoglobin; FAST: focused assessment for the sonography of trauma; BD = Base deficit; GCS = Glasgow Coma Scale; INR: international normalized ratio; ISS: Injury Severity Score. Adapted from El-Menyar et al. (2019)¹⁶

essential to designate the professional(s) who will be responsible for implementing the MHP at each center. Most groups determine that this role falls to the senior physician on the team.

The decision to interrupt a MT should be made jointly among the doctors on the resuscitation team and should be communicated immediately to the blood bank. Some groups suggest that the interruption of MT should take into account anatomical criteria (bleeding stopped through surgical control or angioembolization) and physiological criteria (stable or increasing blood pressure and improvement or stability of target organ perfusion measurements).^{13,17,18} When achieved, MHP should be discontinued and, if the patient still requires resuscitation, transfusion therapy should be goal-directed.

Interrupting MT is also justifiable and necessary when the care team determines that there is no longer any benefit for the patient in question, when the injury or process is considered irreversible. However, early recognition of the futility of MT is a challenge and current studies have not yet identified variables that can accurately determine the risk of early mortality.¹⁹

Initial clinical assessment, and physiological, biochemical and metabolic parameters

In the event of critical bleeding, it is essential to identify the cause of the bleeding and control it as quickly as possible. Common causes of critical bleeding include trauma, gastrointestinal bleeding, ruptured aortic aneurysm, obstetric hemorrhage and surgical procedures. The first signs of blood loss are not always recognized however, significant blood loss triggers a sequence of physiological responses to maintain cardiac output and preserve blood flow to vital organs. Thus, physiological changes and biochemical parameters can be used to recognize a critical hemorrhage.

In patients with critical bleeding who require MHP, it is recommended that, in addition to monitoring physiological parameters, the following parameters are measured early and frequently:⁸

- Temperature
- Acid-base state
- Ionic calcium
- Hemoglobin/platelet count
- Prothrombin time (PT)/INR/Activated partial thromboplastin time (APTT)
- Fibrinogen

Critical targets

- Temperature $\geq 35^{\circ}\text{C}$
- pH ≥ 7.2
- Base deficit ≥ -6 mmol/L
- Lactate ≤ 4 mmol/L
- $\text{Ca}_2^{+} \geq 1.0$ mmol/L
- Platelet count $> 50 \times 10^9/\text{L}$

- PT/APTT ≤ 1.5
- Fibrinogen ≥ 2.0 g/L

*Some groups suggest repeating these parameters every four units of packed red blood cells transfused. This periodicity must be defined and adapted locally.

Proportion between red blood cells and other blood components, time and dose

In the MHP, red blood cells and other blood components are made available in 'transfusion packages' following fixed or pre-defined ratios of red blood cell concentrate (RBCC): fresh frozen plasma (FFP): platelets (PLT). The most commonly used ratios are 1:1:1 and 2:1:1 of RBCC:FFP:PLT, respectively.

Studies that evaluated the impact on mortality of using ratios 1:1:1 (high) and 2:1:1 (low) in the transfusion of patients with critical bleeding showed conflicting results^{15,17,20-24} and therefore there is no way to define the best RBCC:FFP:PLT ratio.

Most groups suggest using at least the 2:1:1 ratio of RBCC:FFP:PLT. The choice and adaptation of this proportion must take into account local characteristics such as stock, storage availability, preparation time, durability of blood components (mainly platelets), among others.

An example of a 1:1:1 package would be four units of RBCC, four units of FFP, and four units of whole blood donor-derived platelets*. In the package with a 2:1:1 ratio the RBCC would be doubled (eight units).

*The transfusion unit available in each center may be different. For example, centers may make platelets derived from apheresis collection available, where one platelet apheresis unit generally corresponds to six units of platelets derived from whole blood donors. Therefore, just like the proportion used, the constitution of the packages must also be adapted to the local reality.

Blood components and products

Blood components refer to RBCC, FFP, PLT as discussed in the previous item, and cryoprecipitate (CRIO).

Blood products refer to plasma derivatives or plasma-derived proteins, such as fibrinogen concentrate and prothrombin complex concentrate, resulting from the fractionation of large amounts of human plasma. Fibrinogen is a key coagulation protein required for the formation of stable clots and is the first coagulation factor to reach critically low levels during bleeding. Replacement can be done using CRIO or fibrinogen concentrate where the most appropriate alternative must be defined locally depending on availability and cost etc. There is not enough evidence to establish the best time or optimal dose for fibrinogen replacement during MHP. In most protocols, this replacement is guided by the results of laboratory coagulation tests or viscoelastic hemostatic assays (VHAs).⁸

It must be considered that, in some centers where thawed plasma is not kept, the FFP transfusion may not be started at the same time as the RBCC transfusion, resulting in significant delays in obtaining the RBCC:FFP ratio.²⁵ During this interval, the fibrinogen level is likely to be lower than desired.

Therefore, some centers use fibrinogen concentrate to quickly restore fibrinogen levels.^{9,26}

The prothrombin complex concentrate is reserved for reversing the action of coumarin anticoagulants at a dose of 25 –50 IU/kg.⁸

Antifibrinolytics

Tranexamic acid has been used in trauma patients in the pre-hospital context or started within three hours after the trauma (at a dose of 1 g, with a second administration at the same dose in eight hours) after the publication of the results of the CRASH-2 study.²⁷ The decrease in the early mortality rate led to the inclusion of tranexamic acid on the World Health Organization Model List of Essential Medicines for the treatment of trauma in 2011.²⁸ A recent study (PATCH-Trauma) showed similar results in reducing the mortality rate in 24 h and 28 days, without evidence of an increase in thrombotic events in a group using tranexamic acid.²⁹ Therefore, most groups recommend the administration of tranexamic acid (up to three hours after injury) as part of the MHP in patients with critical bleeding.

The use of tranexamic acid in women with postpartum hemorrhage is recommended by some groups due to the results of the WOMAN study, which showed a lower rate of mortality related to bleeding in the group of patients who received the medication (mainly less than three hours after the onset of bleeding). The tranexamic acid regimen used was 1 g, which could be repeated in 30 min (if the bleeding was uncontrolled) or in 24 h (if rebleeding).^{8,30}

A possible benefit of using tranexamic acid has been suggested for gastrointestinal (GI) tract bleeding, particularly upper GI tract bleeding.³² Recently, however, the HALT-IT randomized study, involving 12,009 patients with GI tract bleeding, did not show a reduction in the mortality rate in patients who received tranexamic acid when compared to those who received placebo.³¹ Therefore, there is no evidence to support the use of antifibrinolytics in patients with GI bleeding.

Viscoelastic hemostatic assay (VHA)

VHAs are tests that provide, from a whole blood sample, a functional assessment of clot formation, clot strength and its degradation. VHAs can be used in critically bleeding patients to assess coagulopathies and guide antifibrinolytic and blood component/product therapy as part of a MHP. Interpreting the results requires specific knowledge and training.

In the setting of critical bleeding management in the MHP, evidence is limited in showing superiority of results for transfusion guided by VHAs over transfusion guided by conventional coagulation tests. Furthermore, the use of these tests involves availability, logistics, training and costs that must be adapted to the reality of the institution. Some societies, such as the Australia Society, suggest that VHA, if used in this context, should be used in conjunction with an established MHP.⁸

Massive hemorrhage protocol (MHP) adaptation

The MHP must be adapted to local institutional needs and resources (access to blood components/products/medicines, stock, transportation, distance between the care service and the service responsible for transfusion support, time for preparation, laboratory support and ease of communication with the blood therapist/hematologist). The very definition of the proportion of blood components for transfusion and the constitution of transfusion packages need to be adapted to local conditions, as discussed previously. Furthermore, the MHP can be modified to address specific populations such as obstetric patients, with the potential for occult hemorrhage and the early development of disseminated intravascular coagulation (DIC), for example.

Adverse events

Transfusions are not without risk. The risk of transfusion reactions must be considered when utilizing a MHP. Complications such as transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), transmission of infectious diseases (including prion diseases), ABO incompatibility, and allergic reactions can contribute to poor patient outcomes.

Therefore, the decision to transfuse must take into account the entire range of available treatments, evaluate the evidence of effectiveness against the risks associated with transfusion and, finally, consider the patient's values and choices.

Recommendations

- A multidisciplinary approach must be used for critical bleeding, aiming at bleeding control, correction of coagulopathies and normalization of physiological parameters.
- It is essential to identify the cause of the bleeding and control it as soon as possible.
- Critical bleeding should not be managed with transfusion alone.
- It is recommended that a MHP be established to care for patients with critical bleeding.
- The MHP must be adapted to local institutional needs and resources.
- It is essential to establish effective communication between the transfusion agency and the care team.
- Implementation of the protocol must be carried out by an experienced professional defined in advance, as there is no consensus on the best predictive score for severe bleeding and the need for massive transfusion.
- Interrupting the MHP protocol at the correct moment and immediate communication to the transfusion agency are essential to minimize losses and the best use of blood components.
- Implementation of the MHP must be carefully weighed as transfusions are not without risk.

Conclusion

In conclusion, the adoption of a Patient Blood Management (PBM) approach to the treatment of serious bleeding highlights a fundamental shift in healthcare towards more efficient and patient-centered care. By prioritizing meticulous bleeding control, comprehensively addressing coagulation challenges and promoting multidisciplinary collaboration, PBM not only increases patient safety but also minimizes excessive dependence on blood products and transfusions. This conscious use of blood products and exploration of viable transfusion alternatives not only reduces the risks associated with transfusions, but also optimizes resource allocation. In the evolving landscape of healthcare, PBM stands as a beacon of comprehensive and insightful care, ultimately providing superior outcomes for patients facing severe bleeding scenarios.

Conflicts of interest

None.

REFERENCES

- Davis JS, Satahoo SS, Butler FK, Dermer H, Naranjo D, Julien K, et al. An analysis of prehospital deaths: who can we save? *J Trauma Acute Care Surg.* 2014;77(2):213.
- Goolsby C, Rouse E, Rojas L, Goralnick E, Levy MJ, Kirsch T, et al. Post-mortem evaluation of potentially survivable hemorrhagic death in a civilian population. *J Am Coll Surg.* 2018;227(5):502.
- Pegu B, Thiagaraju C, Nayak D, Subbaiah M. Placenta accreta spectrum—a catastrophic situation in obstetrics. *Obstet Gynecol Sci.* 2021;64(3):239–47.
- Meyer DE, Vincent LA, Fox EE, O’Keeffe T, Inaba K, Bulger E, et al. Every minute counts: time to delivery of initial massive transfusion cooler and its impact on mortality. *J Trauma Acute Care Surg.* julho de. 2017;83(1):19–24.
- MD, PhD1,2,3PhD3 Lee Seung Mi, Lee Garam, Kim Tae Kyong, et al. Dezembro de 2022. Development and validation of a prediction model for need for massive transfusion during surgery using intraoperative hemodynamic monitoring data. *JAMA Netw Open.* 2022;5(12):e2246637.
- American College of Surgeons. Massive transfusion in trauma guidelines. 2014. Available at: https://www.facs.org/media/zcjdtrd1/transfusion_guidelines.pdf
- Meneses E, Boneva D, McKenney M, Elkbuli A. Massive transfusion protocol in adult trauma population. *Am J Emerg Med.* 2020;38(12):2661–6.
- NATIONAL BLOOD AUTHORITY. Patient blood management guideline for adults with critical bleeding. 2023. Available at: <https://www.blood.gov.au/system/files/documents/Guideline%20Patient%20blood%20management%20guideline%20for%20adults%20with%20critical%20bleeding.pdf>
- Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. *Crit Care.* 2019;23(1):98.
- Vlaar APJ, Dionne JC, de Bruin S, Wijnberge M, Raasveldt SJ, van Baarle FEHP, et al. Transfusion strategies in bleeding critically ill adults: a clinical practice guideline from the European society of intensive care medicine: guidelines. *Intensive Care Med.* 2021;47(12):1368–92.
- Mitra B, Cameron PA, Gruen RL, Mori A, Fitzgerald M, Street A. The definition of massive transfusion in trauma: a critical variable in examining evidence for resuscitation. *Eur J Emerg Med.* 2011;18(3):137.
- Zatta AJ, McQuilten ZK, Mitra B, Roxby DJ, Sinha R, Whitehead S, et al. Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. *Vox Sang.* 2014;107(1):60–70.
- Cantle PM, Cotton BA. Prediction of Massive Transfusion in Trauma. *Crit Care Clin.* 2017;33(1):71–84.
- Hess JR, Zimrin AB. Massive blood transfusion for trauma. *Curr Opin Hematol.* 2005;12(6):488.
- Kleinvelde DJB, van Amstel RBE, Wirtz MR, Geeraedts LMG, Gosslings JC, Hollmann MW, et al. Platelet-to-red blood cell ratio and mortality in bleeding trauma patients: a systematic review and meta-analysis. *Transfusion (Paris).* 2021;61(S1):S243–51.
- El-Menyar A, Mekkodathil A, Abdelrahman H, Latifi R, Galwankar S, Al-Thani H, et al. Review of existing scoring systems for massive blood transfusion in trauma patients: where do we stand? *Shock.* 2019;52(3):288.
- Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA.* 2015;313(5):471–82.
- Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, et al. Pragmatic randomized optimal platelet and plasma ratios (PROPPR) Trial: design, rationale and implementation. *Injury.* 1 de setembro de. 2014;45(9):1287–95.
- Mladinov D, Frank SM. Massive transfusion and severe blood shortages: establishing and implementing predictors of futility. *Br J Anaesth.* 2022;128(2):e71–4.
- Rahouma M, Kamel M, Jodeh D, Kelley T, Ohmes LB, de Biasi AR, et al. Does a balanced transfusion ratio of plasma to packed red blood cells improve outcomes in both trauma and surgical patients? A meta-analysis of randomized controlled trials and observational studies. *Am J Surg.* Agosto de. 2018;216(2):342–50.
- McQuilten ZK, Crichton G, Brunskill S, Morison JK, Richter TH, Waters N, et al. Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review. *Transfus Med Rev.* Janeiro de. 2018;32(1):6–15.
- da Luz LT, Shah PS, Strauss R, Mohammed AA, D’Empaire PP, Tien H, et al. Does the evidence support the importance of high transfusion ratios of plasma and platelets to red blood cells in improving outcomes in severely injured patients: a systematic review and meta-analyses. *Transfusion (Paris).* Novembro de. 2019;59(11):3337–49.
- Rijnhout TWH, Duijst J, Noorman F, Zoodsma M, van Waes OJF, Verhofstad MHJ, et al. Platelet to erythrocyte transfusion ratio and mortality in massively transfused trauma patients. A systematic review and meta-analysis. *J Trauma Acute Care Surg.* 1 de outubro de. 2021;91(4):759–71.
- Nascimento B, Callum J, Tien H, Rubenfeld G, Pinto R, Lin Y, Rizoli S. Effect of a fixed-ratio (1:1:1) transfusion protocol versus laboratory-results-guided transfusion in patients with severe trauma: a randomized feasibility trial. *CMAJ.* 2013;185(12):E583–9.
- Halmin M, Boström F, Brattström O, Lundahl J, Wikman A, Östlund A, et al. Effect of plasma-to-RBC ratios in trauma patients: a cohort study with time-dependent data*. *Crit Care Med.* Agosto de. 2013;41(8):1905–14.
- Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, et al. Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. *Crit Care.* 2015;19(1):83.
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant

- haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *The Lancet*. 2010;376(9734):23–32.
28. WHO. Tranexamic acid. eEML - Electronic Essential Medicines List. Available at: <https://list.essentialmeds.org/recommendations/152>.
 29. The PATCH-Trauma Investigators and the ANZICS Clinical Trials Group. Prehospital tranexamic acid for severe trauma. 2023. *N Engl J Med*. 2023;389:127–36.
 30. Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akin-tan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *The Lancet*. 2017;389(10084):2105–16.
 31. Roberts I, Shakur-Still H, Afolabi A., Akere A., Arribas M., Brenner A., et al. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. *The Lancet*. 2020;395(10241):1927–36.
 32. Lee PL, Yang KS, Tsai HW, Hou SK, Kang YN, Chang CC. Tranexamic acid for gastrointestinal bleeding: a systematic review with meta-analysis of randomized clinical trials. *Am J Emerg Med*. 2021;45:269–79.